Matches in SemOpenAlex for { <https://semopenalex.org/work/W2430969673> ?p ?o ?g. }
Showing items 1 to 76 of
76
with 100 items per page.
- W2430969673 endingPage "6" @default.
- W2430969673 startingPage "272" @default.
- W2430969673 abstract "A significant portion of patients with psoriasis have scalp and nail involvement. It has been reported that 40% to 45% of patients with psoriasis have nail psoriasis, and up to 80% have scalp involvement. Nail and scalp psoriasis have often been found to be difficult to treat, due to the poor penetration and poor compliance of topical medication. Oral and biologic therapies have shown significant efficacy but often with undesirable side effects. Herein, we analyze the efficacy of apremilast, an oral phosphodiesterase-4 (PDE-4) inhibitor, in the treatment of nail and scalp psoriasis at 16-, 32-, and 52 weeks.We reviewed the results of the phase IIb and phase III clinical trials for apremilast in treating nail and scalp psoriasis.In ESTEEM 1, patients on apremilast showed a 22.5%, 43.6%, and 60.2% improvement in NAPSI at weeks 16, 32, and 52. 33.3%, 45.2%, and 63% of patients achieved NAPSI-50, respectively. In ESTEEM 2, patients on apremilast showed a 29%, 60%, and 59.7% improvement in NAPSI at weeks 16, 32, and 52, with 44.6%, 55.4%, and 68.6% of patients achieving NAPSI-50. In PSOR-005 at week 16, patients on a dose of 30 mg twice weekly had a 42.9% improvement in NAPSI with 45.5% reaching NAPSI-50. For scalp psoriasis, 46.5%, 37.4%, and 73% of patients achieved an Sc-PGA of 0 or 1 at weeks 16, 32, and 52 in ESTEEM 1. In ESTEEM 2, 40.9%, 32.4%, and 62.5% of patients achieved an Sc-PGA of 0 or 1 at weeks 16, 32, and 52.With its limited safety profile of only diarrhea and headache and no additional lab requirements, apremilast may be a safer and more convenient alternative for patients with severe nail and scalp psoriasis." @default.
- W2430969673 created "2016-06-24" @default.
- W2430969673 creator A5003620848 @default.
- W2430969673 creator A5030370364 @default.
- W2430969673 creator A5043197838 @default.
- W2430969673 creator A5069063369 @default.
- W2430969673 creator A5071806545 @default.
- W2430969673 creator A5081552762 @default.
- W2430969673 date "2016-03-01" @default.
- W2430969673 modified "2023-09-23" @default.
- W2430969673 title "Improvement of Nail and Scalp Psoriasis Using Apremilast in Patients With Chronic Psoriasis: Phase 2b and 3, 52-Week Randomized, Placebo-Controlled Trial Results." @default.
- W2430969673 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26954311" @default.
- W2430969673 hasPublicationYear "2016" @default.
- W2430969673 type Work @default.
- W2430969673 sameAs 2430969673 @default.
- W2430969673 citedByCount "4" @default.
- W2430969673 countsByYear W24309696732016 @default.
- W2430969673 countsByYear W24309696732018 @default.
- W2430969673 crossrefType "journal-article" @default.
- W2430969673 hasAuthorship W2430969673A5003620848 @default.
- W2430969673 hasAuthorship W2430969673A5030370364 @default.
- W2430969673 hasAuthorship W2430969673A5043197838 @default.
- W2430969673 hasAuthorship W2430969673A5069063369 @default.
- W2430969673 hasAuthorship W2430969673A5071806545 @default.
- W2430969673 hasAuthorship W2430969673A5081552762 @default.
- W2430969673 hasConcept C126322002 @default.
- W2430969673 hasConcept C142724271 @default.
- W2430969673 hasConcept C16005928 @default.
- W2430969673 hasConcept C168563851 @default.
- W2430969673 hasConcept C191897082 @default.
- W2430969673 hasConcept C192562407 @default.
- W2430969673 hasConcept C204787440 @default.
- W2430969673 hasConcept C27081682 @default.
- W2430969673 hasConcept C2776260265 @default.
- W2430969673 hasConcept C2777524370 @default.
- W2430969673 hasConcept C2777852167 @default.
- W2430969673 hasConcept C2778515351 @default.
- W2430969673 hasConcept C2780564577 @default.
- W2430969673 hasConcept C2781427535 @default.
- W2430969673 hasConcept C71924100 @default.
- W2430969673 hasConceptScore W2430969673C126322002 @default.
- W2430969673 hasConceptScore W2430969673C142724271 @default.
- W2430969673 hasConceptScore W2430969673C16005928 @default.
- W2430969673 hasConceptScore W2430969673C168563851 @default.
- W2430969673 hasConceptScore W2430969673C191897082 @default.
- W2430969673 hasConceptScore W2430969673C192562407 @default.
- W2430969673 hasConceptScore W2430969673C204787440 @default.
- W2430969673 hasConceptScore W2430969673C27081682 @default.
- W2430969673 hasConceptScore W2430969673C2776260265 @default.
- W2430969673 hasConceptScore W2430969673C2777524370 @default.
- W2430969673 hasConceptScore W2430969673C2777852167 @default.
- W2430969673 hasConceptScore W2430969673C2778515351 @default.
- W2430969673 hasConceptScore W2430969673C2780564577 @default.
- W2430969673 hasConceptScore W2430969673C2781427535 @default.
- W2430969673 hasConceptScore W2430969673C71924100 @default.
- W2430969673 hasIssue "3" @default.
- W2430969673 hasLocation W24309696731 @default.
- W2430969673 hasOpenAccess W2430969673 @default.
- W2430969673 hasPrimaryLocation W24309696731 @default.
- W2430969673 hasRelatedWork W1975604575 @default.
- W2430969673 hasRelatedWork W2019888797 @default.
- W2430969673 hasRelatedWork W2093292193 @default.
- W2430969673 hasRelatedWork W2407322217 @default.
- W2430969673 hasRelatedWork W2430969673 @default.
- W2430969673 hasRelatedWork W2736713079 @default.
- W2430969673 hasRelatedWork W2752549262 @default.
- W2430969673 hasRelatedWork W2893942507 @default.
- W2430969673 hasRelatedWork W2904182792 @default.
- W2430969673 hasRelatedWork W3195838575 @default.
- W2430969673 hasVolume "15" @default.
- W2430969673 isParatext "false" @default.
- W2430969673 isRetracted "false" @default.
- W2430969673 magId "2430969673" @default.
- W2430969673 workType "article" @default.